This Beaten-Down Stock Could Soar by 31%, Says Wall Street
The struggle continues for telemedicine specialist Teladoc (NYSE: TDOC). The company's shares have been in free-fall since 2021 -- down 90% over the past three years -- and it started 2024 with another disappointing quarterly update that further dragged down its stock price. Is there still reason to invest in Teladoc?
Wall Street analysts think so. Their average price target of $20.16 represents an upside of about 31% over the stock's Friday closing price. Can Teladoc bounce back and hit this target within a year?
Teladoc has had a lot to prove for a while. Long gone are the early pandemic days when the company's services were in peak demand. Telehealth provided a decent option for those who were staying away form other people yet still needing healthcare like basics. Teladoc's business hasn't kept things up since. Was the company just a pandemic stock?
Source Fool.com
